CN113476610A - Antifungal medicine composition composed of glycerin derivative and antifungal medicine - Google Patents
Antifungal medicine composition composed of glycerin derivative and antifungal medicine Download PDFInfo
- Publication number
- CN113476610A CN113476610A CN202110930066.0A CN202110930066A CN113476610A CN 113476610 A CN113476610 A CN 113476610A CN 202110930066 A CN202110930066 A CN 202110930066A CN 113476610 A CN113476610 A CN 113476610A
- Authority
- CN
- China
- Prior art keywords
- antifungal
- pharmaceutical composition
- drug
- antifungal medicine
- antifungal pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 24
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 22
- 150000002314 glycerols Chemical class 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 241000222122 Candida albicans Species 0.000 claims abstract description 12
- 229940095731 candida albicans Drugs 0.000 claims abstract description 12
- 239000003429 antifungal agent Substances 0.000 claims abstract description 7
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 11
- 229960004884 fluconazole Drugs 0.000 claims description 11
- -1 p-methoxybenzyl Chemical group 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 7
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 6
- 241000555688 Malassezia furfur Species 0.000 claims description 5
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010020326 Caspofungin Proteins 0.000 claims description 3
- 229960003204 amorolfine Drugs 0.000 claims description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
- 229960003942 amphotericin b Drugs 0.000 claims description 3
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 3
- 229960003034 caspofungin Drugs 0.000 claims description 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004413 flucytosine Drugs 0.000 claims description 3
- 229960004130 itraconazole Drugs 0.000 claims description 3
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 3
- 229960004740 voriconazole Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241001523006 Talaromyces marneffei Species 0.000 claims 2
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 claims 1
- 241000555676 Malassezia Species 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000857964 Ileodictyon cibarium Species 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antifungal medicine composition consisting of a glycerol derivative and an antifungal medicine. Experiments prove that the glycerol derivative and the antifungal drug have the function of obviously inhibiting drug-resistant candida albicans. The application provided by the invention has good medicinal value and application prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an antifungal medicine composition consisting of a glycerol derivative and an antifungal medicine.
Background
Invasive mycosis refers to systemic infectious diseases caused by invasion of tissues, organs and blood by various pathogenic candida, and the most common pathogenic bacteria include candida albicans, candida tropicalis, candida glabrata and candida kininogenes. Most life-threatening fungal infections occur in immunocompromised trauma, high immunosuppressive usage, neutropenia, medical device implantation and organ transplant patients with a mortality rate of about 40%. With the intervention treatment of antibacterial drugs such as fluconazole, the clinical isolate produces drug resistance genes and forms cross resistance with other azole drugs. Making the treatment of invasive mycoses problematic. The inventor finds that glycerol has no antifungal effect in screening medicines, but unexpectedly finds that the derivative of the glycerol has a good synergistic antibacterial effect on drug-resistant candida albicans, which is the first discovery.
Disclosure of Invention
The invention aims to provide an antifungal medicine composition consisting of a glycerol derivative and an antifungal medicine, wherein the structural formula of the glycerol derivative is shown in the specification
(ii) a Wherein R is1= H, PMB (p-methoxybenzyl), n-C15H31CO；R2=H, n-C17H35CO, n-C16H33, n-C18H37。
R1=H；R2= n-C17H35CO。
R1= n-C15H31CO；R2=H。
R1= PMB (p-methoxybenzyl); r2= n-C16H33。
R1= PMB (p-methoxybenzyl); r2=H。
R1=H；R2= n-C18H37。
The antifungal drug is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
The mass ratio of the glycerol derivative to the antifungal medicine is 5: 1.
the fungi are Candida albicans, Marneffei basket fungus, Cryptococcus and Malassezia furfur.
The fungi are Candida albicans resistant strain, Marneffei basket fungus resistant strain, Cryptococcus resistant strain, and Malassezia furfur resistant strain.
The invention has the advantages that:
the invention has the advantages and positive effects that sufficient chemical and pharmacological basis is provided for drug candidates for treating drug-resistant deep fungal infections.
Detailed Description
The present invention is further illustrated but not limited in any way by the following examples, and any modifications made thereto are intended to fall within the scope of the present invention.
The structural formula of the glycerol derivative is
(ii) a Wherein R is1= H, PMB (p-methoxybenzyl), n-C15H31CO；R2=H, n-C17H35CO, n-C16H33, n-C18H37。
R1=H；R2= n-C17H35CO。
R1= n-C15H31CO；R2=H。
R1= PMB (p-methoxybenzyl); r2= n-C16H33。
R1= PMB (p-methoxybenzyl); r2=H。
R1=H；R2= n-C18H37。
The antifungal drug is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
The mass ratio of the glycerol derivative to the antifungal medicine is 5: 1.
the fungi are Candida albicans, Marneffei basket fungus, Cryptococcus and Malassezia furfur.
The fungi are Candida albicans resistant strain, Marneffei basket fungus resistant strain, Cryptococcus resistant strain, and Malassezia furfur resistant strain.
Example 1
Glycerol derivative antifungal activity test:
materials and methods
Medicine and sample
The preparation method of the glycerol derivative comprises the following steps:
glycerol derivatives were synthesized according to the methods described in the literature (Guanghui Ni, Zhiyuan Li, Kangjiang Liang, Ting Wu, Gennaro De Libero, Chengfeng Xia, Synthesis and evaluation of immunological plasma lysophatidyllethanolamine and analogics for native kit T cells, Bioorganic & Medicinal Chemistry 2014, 22 (11): 2966-.
The sample glycerol derivative was dissolved at 100mg/ml and placed in a refrigerator at 4 ℃. Grinding fluconazole, dissolving with DMSO, ultrasonic treating for 10min, centrifuging to obtain supernatant, storing at 50mg/ml, and placing in refrigerator at 4 deg.C.
II, reagent and solution
(1) Reagent
Fluconazole, DMSO
(2) Culture medium
Sabouraud's liquid culture medium
Third, Experimental methods
Taking a 96-well culture plate, diluting the positive drug fluconazole into an initial concentration of 200ug/ml, directly using a storage solution for a sample, directly adding 200ug/ml fluconazole into the storage solution for the sample during drug combination, then diluting by 5 times, carrying out 4 concentration gradients, and repeating 3 wells for each concentration gradient. Adding fungus suspension into each well, wherein the concentration of Candida albicans standard strain is 1 × 105CFU/mL, Candida albicans resistantThe concentration of the drug strain is 1X 105 CFU/mL, cultured at 37 ℃ for 24 h. The OD value at 630nm was measured by a microplate reader. The experiment was also set with a medium blank control, a bacteria solution control and a fluconazole positive drug control.
Fourth, calculation formula
Fungal activity inhibition (%) = (1-sample OD value/Experimental control hole OD value) × 100%
Combination Index (FICI): FICI = MICA/A + MICB/B (where A and B are MIC values for single use of the two drugs, respectively, and MICA and MICB are MIC values for combination of the two drugs, respectively.) when the MIC values are higher than the detection upper limit, a value twice the upper limit concentration is used to calculate the FICI. the MIC50 value in this experiment is calculated as the percentage inhibition of fluconazole at 50% minimal fungal growth. when FICI is less than or equal to 0.5, the two drugs act in a synergistic manner, when FICI is greater than 0.5 and less than or equal to 4, the two drugs act in an unrelated manner, and when FICI is greater than 4, the two drugs act in an antagonistic manner.
The results of the experiments are shown in the following table.
Experimental results show that the glycerin derivative and the antifungal drug fluconazole are combined to have an inhibiting effect on candida albicans drug-resistant bacteria and have a synergistic effect.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110930066.0A CN113476610A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition composed of glycerin derivative and antifungal medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110930066.0A CN113476610A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition composed of glycerin derivative and antifungal medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476610A true CN113476610A (en) | 2021-10-08 |
Family
ID=77945222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110930066.0A Pending CN113476610A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition composed of glycerin derivative and antifungal medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476610A (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011707A1 (en) * | 1995-09-27 | 1997-04-03 | The Liposome Company, Inc. | Modified ether glyceroglycolipids |
| CN1341025A (en) * | 1999-02-26 | 2002-03-20 | 东洋水产株式会社 | Medicinal products containing (sulfopyranosyl)acylglycerol derivatives |
| CN1767765A (en) * | 2003-04-04 | 2006-05-03 | 株式会社资生堂 | Skin preparation composition for external use |
| CN100998673A (en) * | 2006-01-12 | 2007-07-18 | 黄石市第一医院 | Compound cream containing fluconazole and Radix scutellariae and its preparing method |
| WO2008075983A2 (en) * | 2006-12-20 | 2008-06-26 | Industrial Research Limited | Analogues of phosphatidylinositol mannosides |
| CN101374501A (en) * | 2006-01-05 | 2009-02-25 | 药物技术公司 | Composition and method of use thereof |
| TW201231074A (en) * | 2011-01-26 | 2012-08-01 | Fpfive Co Ltd | A type of chemical which does not contain preservative or biocide, but can also inhibit microbial proliferation of reproduction |
| CN105228449A (en) * | 2013-05-26 | 2016-01-06 | 西姆莱斯股份公司 | Antimicrobial compositions containing glycerin ether |
| CN109689034A (en) * | 2016-06-13 | 2019-04-26 | 维奥梅治疗有限公司 | Cooperate with antifungal composition and its method |
| CN110403936A (en) * | 2019-09-05 | 2019-11-05 | 杭州百诚医药科技股份有限公司 | A kind of Fluconazole pharmaceutical composition and preparation method thereof |
| CN111494447A (en) * | 2020-06-23 | 2020-08-07 | 云南中医药大学 | Drug-resistant fungus resistant pharmaceutical composition and preparation thereof |
| CN112955113A (en) * | 2018-07-05 | 2021-06-11 | 科莱恩国际有限公司 | Antimicrobial binding compositions comprising glycerol derivatives and bicyclic compounds |
-
2021
- 2021-08-13 CN CN202110930066.0A patent/CN113476610A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011707A1 (en) * | 1995-09-27 | 1997-04-03 | The Liposome Company, Inc. | Modified ether glyceroglycolipids |
| CN1341025A (en) * | 1999-02-26 | 2002-03-20 | 东洋水产株式会社 | Medicinal products containing (sulfopyranosyl)acylglycerol derivatives |
| CN1767765A (en) * | 2003-04-04 | 2006-05-03 | 株式会社资生堂 | Skin preparation composition for external use |
| CN101374501A (en) * | 2006-01-05 | 2009-02-25 | 药物技术公司 | Composition and method of use thereof |
| CN100998673A (en) * | 2006-01-12 | 2007-07-18 | 黄石市第一医院 | Compound cream containing fluconazole and Radix scutellariae and its preparing method |
| WO2008075983A2 (en) * | 2006-12-20 | 2008-06-26 | Industrial Research Limited | Analogues of phosphatidylinositol mannosides |
| TW201231074A (en) * | 2011-01-26 | 2012-08-01 | Fpfive Co Ltd | A type of chemical which does not contain preservative or biocide, but can also inhibit microbial proliferation of reproduction |
| CN105228449A (en) * | 2013-05-26 | 2016-01-06 | 西姆莱斯股份公司 | Antimicrobial compositions containing glycerin ether |
| CN109689034A (en) * | 2016-06-13 | 2019-04-26 | 维奥梅治疗有限公司 | Cooperate with antifungal composition and its method |
| CN112955113A (en) * | 2018-07-05 | 2021-06-11 | 科莱恩国际有限公司 | Antimicrobial binding compositions comprising glycerol derivatives and bicyclic compounds |
| CN110403936A (en) * | 2019-09-05 | 2019-11-05 | 杭州百诚医药科技股份有限公司 | A kind of Fluconazole pharmaceutical composition and preparation method thereof |
| CN111494447A (en) * | 2020-06-23 | 2020-08-07 | 云南中医药大学 | Drug-resistant fungus resistant pharmaceutical composition and preparation thereof |
Non-Patent Citations (5)
| Title |
|---|
| DEBING PU，等: "Triterpenoids from Ganoderma gibbosum: A Class of Sensitizers of FLC-Resistant Candida albicans to Fluconazole", 《J NAT PROD》 * |
| HOE-SUP BYUN，等: "Enantioselective Syntheses of 1-O-Ben zyl-sn-glycerol and 1-O-Hexadecyl-2-O-methyI-sn-glyceroI via Asymmetric Dihydroxylation of Allyl 4-Methoxyphenyl Ether. Use of AD-Mix Supplemented with Potassium Persulfate", 《J. ORG. CHEM.》 * |
| JIANHUA JIA，等: "Optically Pure Diphenoxy Derivatives as More Flexible Probes forβ‑Amyloid Plaques", 《ACS CHEM. NEUROSCI.》 * |
| 邱丽娟 等: "硬脂酸单甘油酯协同卡泊芬净的体外抗念珠菌活性研究" * |
| 郑书国，等: "《药理学 第3版》", 31 August 2020, 中国科学技术大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2368078T3 (en) | PHARMACEUTICAL COMPOSITION AND METHOD USED BY AN ANTIFUNGICAL AGENT IN COMBINATION. | |
| JP7322259B2 (en) | Dosage Regimens for Treatment of Fungal Infections | |
| Shukla et al. | Past, present, and future of antifungal drug development | |
| JP7574268B2 (en) | Concomitant antifungal agents | |
| Yakovychuk et al. | Аntifungal activity of 5-(2-nitrovinyl) imidazoles and their derivatives against the causative agents of vulvovaginal candidiasis | |
| JP7214714B2 (en) | Antifungal agents exhibiting enhanced activity at acidic pH | |
| CN113476610A (en) | Antifungal medicine composition composed of glycerin derivative and antifungal medicine | |
| WO2014115487A1 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus | |
| CN113559268A (en) | An antifungal pharmaceutical composition | |
| CN110403943B (en) | Application of CC-115 in the preparation of antifungal drugs and its pharmaceutical composition | |
| CN113559087A (en) | Antifungal drug composition composed of 3,4-di-O-benzylphytosphingosine and antifungal drug | |
| Shen et al. | New azole derivatives linked to indole/indoline moieties combined with FLC against drug-resistant Candida albicans | |
| CN110327347B (en) | Application of G-749 in preparing antifungal medicine | |
| CN105010342A (en) | Method for using 3-aryl-5-methylbutyrolactone compounds as plant pathogenic fungus killing agent | |
| CN108354926B (en) | Application of scutellarin and derivatives thereof in antifungal medicines | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases | |
| CN103356628B (en) | Use of pyrazolopyrimidine compound in pharmacy | |
| CN103356625B (en) | Application of Thrazolopyrimidines in Candida parapsilosis Infectious Diseases | |
| CN111714497B (en) | Application of antipyrine derivatives in the preparation of products for inhibiting Candida albicans | |
| CN111991389A (en) | Use of SB-743921 for the preparation of antifungal drugs | |
| CN103405439B (en) | Application of pyrimidine compound to preparing antifungal medicines | |
| CN110639017A (en) | A pharmaceutical composition for inhibiting Candida albicans | |
| CN107261146A (en) | A kind of Sodium Houttuyfonate prepares the composition for killing resistance aspergillus fumigatus and its application | |
| Hamdi et al. | Evaluation of the Anti-Candida effect of Garlic, Shallot and Onion to inhibit the Quorum Sensing Activity. | |
| EP4275681A1 (en) | Active compounds for medical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |